AstraZeneca Shares Rise 2.7% as Tezspire Data Support Expansion Case
AstraZeneca shares traded at $168.38, up approximately 2.71% on October 20. The Fly reported detailed phase 3 CROSSING results for Tezspire, while the commercial payoff remains unproven.
AstraZeneca NYSE:AZN has more clinical evidence behind Tezspire's expansion. The commercial payoff still needs proving. Shares traded at $168.38, up approximately 2.71% on October 20, while The Fly reported detailed CROSSING results at 12.15pm ET. The phase 3 trial tested Tezspire in eosinophilic e…